## Sodium Chloride 3%

### Newborn Use Only

### Alert
- Osmolarity: 1027 mOsm/L. Sodium supplementation is not always appropriate and fluid restriction may be appropriate in the management of hyponatraemia. Treatment should always be tailored to the cause.

### Indication
- Treatment of hyponatraemia.

### Action
- Sodium is the major cation of extracellular fluid.

### Drug Type
- Sodium chloride 3% contains 30 g/L sodium chloride, equivalent to 0.5 mmol/mL of sodium.

### Trade Name
- Sodium chloride 3%

### Presentation
- Sodium chloride 3% – 1000 mL.

### Dosage/Interval
- **Severe hyponatraemia < 120 mmol/L or symptomatic hyponatraemia**
  - IV: Give sodium chloride 3% at 0.5 mmol/kg/hour (1 mL/kg/hour) until symptoms abate or sodium ≥ 120 mmol/L.*
  - Then give sodium chloride 3% at 0.15 mmol/kg/hour (0.3 mL/kg/hour) for 48 hours or until desired sodium is achieved.
  - [Therapeutic goal is to increase sodium by 7 mmol/L/day]
  - *1 mL/kg sodium chloride 3% will raise serum sodium by approximately 1 mmol/L.²

### IV supplementation
- Start at 2–4 mmol/kg/day and increase as required.

### Route
- IV

### Maximum Dose
-

### Preparation/Dilution
- IV: Sodium chloride 3% can be given undiluted.

### Administration
- IV:
  - Sodium chloride 3% – Can be given undiluted as an infusion, preferably through large vein.

### Monitoring
- IV: Watch the local site for signs of extravasation.
  - Monitor serum sodium as per clinical team's recommendation.

### Contraindications
- IV: No information.

### Precautions
- Impaired renal function, cardiac insufficiency, pre-existing oedema with sodium retention.

### Drug Interactions
- No information.

### Adverse Reactions
- Hyponatraemia, volume overload, congestive heart failure, respiratory distress.
- Hyperchloraeemia, hypercalciuria.
- Disseminated intravascular coagulation (DIC) is associated with inadvertent injections of sodium chloride into blood vessels of the uterus or placenta due to hyponatraemic shock; not reported in infants.
- Osmotic demyelinating syndrome.
- Fever.
- IV site: Extravasation, phlebitis, venous thrombosis.

### Compatibility
- **IV Fluids:** Glucose 5%, glucose 10%, glucose 5% in sodium chloride 0.9%, glucose 5% in sodium chloride 0.45%, sodium chloride 0.9%, sodium chloride 0.45%.
  - Y site: No information.

### Incompatibility
- **IV Fluids:** Fat emulsion.
  - Y site: No information.
  - Amino acid solutions – No information.

### Stability
- **Storage:** Store at room temperature, 20–25°C

### Special Comments
- Osmolarity of undiluted hypertonic sodium chloride is > 1000 mOsm/L, posing the risk of extravasation for peripheral IV solutions.³ ⁴ Monitor for extravasation when infused peripherally at higher rates.
### Evidence summary

**Total body water** is traditionally calculated as weight x 0.6 in children. Greater total body water content in newborns should be considered and therefore should be calculated as weight x 0.75.  

<table>
<thead>
<tr>
<th><strong>IV correction for severe and/or symptomatic hyponatraemia</strong></th>
</tr>
</thead>
</table>
| The body of evidence to base recommendations in this clinical setting is extremely limited, particularly in neonatal populations. Recommendations are based on expert opinion, which have been extrapolated from adult consensus guidelines and take into account specific neonatal safety concerns (see Safety below). In acute hyponatraemia, where the risk of sequelae is greater than that of osmotic demyelination, the correction should be rapid.  
| Aim to increase sodium by 1–2 mmol/L per hour until symptoms abate or a safe level of sodium is achieved (≥ 120 mmol/L). Once the safe level is achieved, suggested subsequent goals are 6–8 mmol/L in 24 hours, 12–14 mmol/L in 48 hours and 14–16 mmol/L in 72 hours. (LOE IV, GOR C) |

**Sodium deficit calculation**

Deficit in mmol = (desired sodium – serum sodium) x total body water  

| **Oral supplementation** |
| A randomised, controlled trial of 4 mmol/kg/d of sodium versus placebo from DOL 7 to 35 in infants born 24–31 weeks (53 infants) showed higher sodium levels and increased weight gain in the intervention group. A randomised, controlled trial of 4 mmol/kg/d of sodium versus placebo from DOL 4 to 14 in infants born at 29–34 weeks (20 infants) showed higher sodium levels and increased weight gain in the intervention group. There are also three case-control studies that report similar findings with respect to sodium levels and growth in preterm infants supplemented with oral sodium. A systematic review comparing higher versus lower sodium intake showed similar findings with respect to sodium levels and growth in preterm infants supplemented with oral sodium. These findings support the use of oral sodium supplements to correct hyponatraemia and potentially improve growth. (LOE II, GOR B) |

| **Safety** |
| An historical case-control study identified 42/350 (12%) ELBW NICU admissions with an episode of hyponatraemia (Na < 125 mmol/L [range 113–124]) that lasted > 6 hours (median 1.5 days). Rates of abnormal head ultrasound (IVH or PVL) and abnormal neurological examination were higher in the hyponatremic group (p < 0.03; p < 0.001 respectively). Correction ≥ 0.5 mmol/L/h showed a trend toward higher rates of abnormal neurological examination. In paediatric and adult populations, multiple cohort studies and reviews have concluded that in patients with chronic hyponatraemia (≥ 48 hours), neurologic sequelae due to osmotic demyelination are associated with more rapid rates of correction.  
| In summary, rapid correction of hyponatraemia may be detrimental to neurological outcome during myelination of the newborn brain. In adult populations, osmotic demyelination syndrome can usually be avoided by limiting correction of chronic hyponatremia to < 10 to 12 mmol/L in 24 hours and to < 18 mmol/L in 48 hours. These estimates should be regarded as approximate limits and not goals of therapy. (LOE IV, GOR C) |

| **Osmolarity and Osmolar load** |
| A retrospective, matched-cohort study of 352 children ≤ 18 years evaluated the incidence of phlebitis or infiltration associated with peripheral administration of parenteral nutrition with an osmolarity >1000 mOsm/L vs ≤1000 mOsm/L. There were 151 neonates in the study. There were no differences between patients who did or did not develop adverse events in terms of age or weight. Administration of PPN with osmolarity >1000 mOsm/L vs ≤ 1000 mOsm/L significantly increased infiltration (17% vs 7%; odds ratio [OR], 2.47; 95% confidence interval [CI], 1.24–4.94; p = 0.01) and the combined composite end point of phlebitis or infiltration (45% vs 34%; OR, 1.65; 95% CI, 1.07–2.54; p = 0.02). In multivariate analysis, osmolarity >1000 mOsm/L was an
independent risk factor for developing complications (OR, 1.67; 95% CI, 1.08–2.52; p = 0.02).\(^\text{18}\) (LOE III, GOR C)

A prospective, observational study in adults suggests that osmolar load (i.e. number of milliosmoles per hour, calculated as osmolarity x infusion rate) is a better predictor than osmolarity alone for phlebitis.\(^\text{19}\) They found an osmolarity rate of 84–99 mOsm/hour was associated with a 4–27% rate of phlebitis. They did not report on other injuries such as extravasation. The infusion rates suggested in our formulary have low osmolar load and are considered to carry minimal risk of phlebitis (Consensus opinion).

### References

### Authors Contribution

<table>
<thead>
<tr>
<th>Role</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original author/s</td>
<td>Chris Wake, Srinivas Bolisetty</td>
</tr>
<tr>
<td>Pharmacy Review</td>
<td>Ushma Trivedi</td>
</tr>
<tr>
<td>Expert review</td>
<td></td>
</tr>
<tr>
<td>Evidence Review</td>
<td>Timothy Schindler</td>
</tr>
<tr>
<td>Final content and editing review</td>
<td>Ian Whyte</td>
</tr>
<tr>
<td>Facilitator/s</td>
<td>Srinivas Bolisetty</td>
</tr>
</tbody>
</table>